FDA Approves New Biosimilars to Denosumab with an Interchangeable Designation
The FDA has approved the first interchangeable biosimilars for denosumab. (Source: The Rheumatologist)
Source: The Rheumatologist - April 18, 2024 Category: Rheumatology Authors: Michele B. Kaufman, PharmD, BCGP Tags: Biologics/DMARDs Conditions Drug Updates Osteoarthritis and Bone Disorders denosumab denosumab-bbdz Jubbonti Prolia Wyost Xgeva Source Type: research
Denosumab ‐induced autoimmune hepatitis: Case report
This report described a patient not known to have a hepatic disease, found to have a drug-induced autoimmune hepatitis from denosumab. This is an unreported side effect, and here, we presented the possible predisposing factors and suggested monitoring parameters. (Source: Clinical Case Reports)
Source: Clinical Case Reports - April 17, 2024 Category: General Medicine Authors: Jawaher J. Alotaibi,
Bushra Albuqami,
Wadha Alotaibi,
Rawan M. Al Ghamdi,
Mohammed Alaskar,
Hadi Kuriry,
Nasser Almasri Tags: CASE REPORT Source Type: research
The cost-effectiveness of osteoporosis medications for preventing periprosthetic fractures following femoral neck fracture indicated hip arthroplasty: a break-even analysis
ConclusionThe utilization of lower cost osteoporosis medications such as oral bisphosphonates and estrogen hormonal therapy as PPF prophylaxis in this patient population would be economically viable if they reduce the PPF rate by 1.8% and 1.5%, respectively. For IV bisphosphonates and newer agents to be economically viable as PPF prophylaxis in the USA, their costs need to be significantly reduced. (Source: Osteoporosis International)
Source: Osteoporosis International - April 15, 2024 Category: Orthopaedics Source Type: research
Delayed and significant hypercalcaemia due to teriparatide therapy: a case report and review
We report the case of a female who developed significant delayed hypercalcaemia after teriparatide treatment for osteoporosis and review other cases in the literature to date.Case reportA 72-year-old female on teriparatide for the treatment of osteoporosis was found to have hypercalcaemia (3.30 mmol/l) on routine testing approximately 3 months after starting therapy. Serum calcium pretreatment was normal at 2.39 mmol/l. She was admitted to the hospital for investigations which identified a serum 25-hydroxyvitamin D of 94 nmol/l, a low parathyroid hormone of 6.0 pg/ml, and normal test results for 1,25 dihydroxyvitamin D (11...
Source: Osteoporosis International - April 13, 2024 Category: Orthopaedics Source Type: research
Bisphosphonates Maintain BMD after Sequential Teriparatide and Denosumab in Premenopausal Women with Idiopathic Osteoporosis
CONCLUSION: BMD remained stable in women with PremenIOP who received bisphosphonates after sequential teriparatide-denosumab therapy.PMID:38605469 | DOI:10.1210/clinem/dgae240 (Source: The Journal of Clinical Endocrinology and Metabolism)
Source: The Journal of Clinical Endocrinology and Metabolism - April 12, 2024 Category: Endocrinology Authors: Mafo Kamanda-Kosseh Stephanie Shiau Sanchita Agarwal Ananya Kondapalli Ivelisse Colon Nayoung Kil Mariana Bucovsky Joan M Lappe Julie Stubby Elizabeth Shane Adi Cohen Source Type: research
Bisphosphonates Maintain BMD after Sequential Teriparatide and Denosumab in Premenopausal Women with Idiopathic Osteoporosis
CONCLUSION: BMD remained stable in women with PremenIOP who received bisphosphonates after sequential teriparatide-denosumab therapy.PMID:38605469 | DOI:10.1210/clinem/dgae240 (Source: The Journal of Clinical Endocrinology and Metabolism)
Source: The Journal of Clinical Endocrinology and Metabolism - April 12, 2024 Category: Endocrinology Authors: Mafo Kamanda-Kosseh Stephanie Shiau Sanchita Agarwal Ananya Kondapalli Ivelisse Colon Nayoung Kil Mariana Bucovsky Joan M Lappe Julie Stubby Elizabeth Shane Adi Cohen Source Type: research
Zoledronate after denosumab discontinuation: Is repeated administrations more effective than single infusion?
CONCLUSIONS: In patients with uncontrolled CTX levels after Dmab withdrawal, two ZOL infusions at 6 months apart do not prevent BMD loss and FX.PMID:38609157 | DOI:10.1210/clinem/dgae224 (Source: The Journal of Clinical Endocrinology and Metabolism)
Source: The Journal of Clinical Endocrinology and Metabolism - April 12, 2024 Category: Endocrinology Authors: Giorgia Grassi Alberto Ghielmetti Marta Zampogna Iacopo Chiodini Maura Arosio Giovanna Mantovani Cristina Eller Vainicher Source Type: research
Bisphosphonates Maintain BMD after Sequential Teriparatide and Denosumab in Premenopausal Women with Idiopathic Osteoporosis
CONCLUSION: BMD remained stable in women with PremenIOP who received bisphosphonates after sequential teriparatide-denosumab therapy.PMID:38605469 | DOI:10.1210/clinem/dgae240 (Source: The Journal of Clinical Endocrinology and Metabolism)
Source: The Journal of Clinical Endocrinology and Metabolism - April 12, 2024 Category: Endocrinology Authors: Mafo Kamanda-Kosseh Stephanie Shiau Sanchita Agarwal Ananya Kondapalli Ivelisse Colon Nayoung Kil Mariana Bucovsky Joan M Lappe Julie Stubby Elizabeth Shane Adi Cohen Source Type: research
Zoledronate after denosumab discontinuation: Is repeated administrations more effective than single infusion?
CONCLUSIONS: In patients with uncontrolled CTX levels after Dmab withdrawal, two ZOL infusions at 6 months apart do not prevent BMD loss and FX.PMID:38609157 | DOI:10.1210/clinem/dgae224 (Source: The Journal of Clinical Endocrinology and Metabolism)
Source: The Journal of Clinical Endocrinology and Metabolism - April 12, 2024 Category: Endocrinology Authors: Giorgia Grassi Alberto Ghielmetti Marta Zampogna Iacopo Chiodini Maura Arosio Giovanna Mantovani Cristina Eller Vainicher Source Type: research
Bisphosphonates Maintain BMD after Sequential Teriparatide and Denosumab in Premenopausal Women with Idiopathic Osteoporosis
CONCLUSION: BMD remained stable in women with PremenIOP who received bisphosphonates after sequential teriparatide-denosumab therapy.PMID:38605469 | DOI:10.1210/clinem/dgae240 (Source: The Journal of Clinical Endocrinology and Metabolism)
Source: The Journal of Clinical Endocrinology and Metabolism - April 12, 2024 Category: Endocrinology Authors: Mafo Kamanda-Kosseh Stephanie Shiau Sanchita Agarwal Ananya Kondapalli Ivelisse Colon Nayoung Kil Mariana Bucovsky Joan M Lappe Julie Stubby Elizabeth Shane Adi Cohen Source Type: research
Zoledronate after denosumab discontinuation: Is repeated administrations more effective than single infusion?
CONCLUSIONS: In patients with uncontrolled CTX levels after Dmab withdrawal, two ZOL infusions at 6 months apart do not prevent BMD loss and FX.PMID:38609157 | DOI:10.1210/clinem/dgae224 (Source: The Journal of Clinical Endocrinology and Metabolism)
Source: The Journal of Clinical Endocrinology and Metabolism - April 12, 2024 Category: Endocrinology Authors: Giorgia Grassi Alberto Ghielmetti Marta Zampogna Iacopo Chiodini Maura Arosio Giovanna Mantovani Cristina Eller Vainicher Source Type: research
GSE248774 Immune modulation with RANKL-blockade through denosumab treatment in cancer patients
We examined whether administering denosumab could modify modulate circulating immune cells in c ancer patients. Blood was collected from 23 prostate cancer patients and 3 renal cell carcinoma patients, who provided written informed consent, with advanced disease who were receiving denosumab, prior to and during denosumab treatment. Using high-dimensional mass cytometry, we found that denosumab treatment by itself induced modest effects on circulating immune cell frequency and activation. We also found minimal changes in the circulating T cell repertoire and the frequency of new thymic emigrants with denosumab treatment. H...
Source: GEO: Gene Expression Omnibus - April 10, 2024 Category: Genetics & Stem Cells Tags: Other Homo sapiens Source Type: research
Advanced renal cell carcinoma management: the Latin American Cooperative Oncology Group (LACOG) and the Latin American Renal Cancer Group (LARCG) consensus update
CONCLUSION: Immunotherapy and targeted therapy are the standards of care for advanced disease. The utilization and sequencing of these therapeutic agents hinge upon individual risk scores and responses to previous treatments. This consensus reflects a commitment to informed decision-making, drawn from professional expertise and evidence in the medical literature.PMID:38594593 | DOI:10.1007/s00432-024-05663-z (Source: Cell Research)
Source: Cell Research - April 9, 2024 Category: Cytology Authors: Andrey Soares Fernando Sabino Marques Monteiro Karine Martins da Trindade Adriano Gon çalves E Silva Ana Paula Garcia Cardoso Andr é Deeke Sasse Andr é P Fay Andr é Paternò Castello Dias Carneiro Antonio Machado Alencar Junior Augusto C ésar de Andr Source Type: research
Advanced renal cell carcinoma management: the Latin American Cooperative Oncology Group (LACOG) and the Latin American Renal Cancer Group (LARCG) consensus update
ConclusionImmunotherapy and targeted therapy are the standards of care for advanced disease. The utilization and sequencing of these therapeutic agents hinge upon individual risk scores and responses to previous treatments. This consensus reflects a commitment to informed decision-making, drawn from professional expertise and evidence in the medical literature. (Source: Journal of Cancer Research and Clinical Oncology)
Source: Journal of Cancer Research and Clinical Oncology - April 9, 2024 Category: Cancer & Oncology Source Type: research
